scholarly journals Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression

2007 ◽  
Vol 6 (8) ◽  
pp. 1269-1274 ◽  
Author(s):  
Dolores Di Vizio ◽  
Federica Sotgia ◽  
Terence M. Williams ◽  
Ghada S. Hassan ◽  
Franco Capozza ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fatty Acid ◽  
Cancer Progression ◽  
Fatty Acid Synthase ◽  
Tumor Promoter ◽  
Prostate Cancer Progression ◽  
Caveolin 1

Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression

The Prostate ◽  
2001 ◽  
Vol 47 (2) ◽  
pp. 102-110 ◽  
Author(s):  
Ellen S. Pizer ◽  
Beth R. Pflug ◽  
G. Steven Bova ◽  
Wan Fang Han ◽  
Michael S. Udan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fatty Acid ◽  
Cancer Progression ◽  
Therapeutic Target ◽  
Fatty Acid Synthase ◽  
Prostate Cancer Progression ◽  
Androgen Independent

scholarly journals Diet-induced alteration of fatty acid synthase in prostate cancer progression

Oncogenesis ◽  
2016 ◽  
Vol 5 (2) ◽  
pp. e195-e195 ◽  
Author(s):  
M Huang ◽  
A Koizumi ◽  
S Narita ◽  
T Inoue ◽  
N Tsuchiya ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fatty Acid ◽  
Cancer Progression ◽  
Fatty Acid Synthase ◽  
Prostate Cancer Progression

MP31-06 DIET INDUCED ALTERATION OF FATTY ACID SYNTHASE IS INVOLVED IN PROSTATE CANCER PROGRESSION

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Mingguo Huang ◽  
Shintaro Narita ◽  
Norihiko Tsuchiya ◽  
Takamitsu Inoue ◽  
Shigeru Satoh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fatty Acid ◽  
Cancer Progression ◽  
Fatty Acid Synthase ◽  
Prostate Cancer Progression

CAVEOLIN-1 INTERACTS WITH A LIPID RAFT-ASSOCIATED POPULATION OF FATTY ACID SYNTHASE IN PROSTATE CANCER

2008 ◽  
Vol 179 (4S) ◽  
pp. 456-457
Author(s):  
Dolores Di Vizio ◽  
Rosalyn M Adam ◽  
Jayoung Kim ◽  
Keith R Solomon ◽  
Robert Kim ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fatty Acid ◽  
Lipid Raft ◽  
Fatty Acid Synthase ◽  
Caveolin 1

Abstract 5165: Fatty acid diversification in prostate cancer progression

2012 ◽  
Author(s):  
Jonathan McDunn ◽  
Matthew Mitchell ◽  
Michael Milburn ◽  
Thomas Wheeler
Keyword(s):  
Prostate Cancer ◽  
Fatty Acid ◽  
Cancer Progression ◽  
Prostate Cancer Progression

scholarly journals Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer

2018 ◽  
Vol 116 (2) ◽  
pp. 631-640 ◽  
Author(s):  
Giorgia Zadra ◽  
Caroline F. Ribeiro ◽  
Paolo Chetta ◽  
Yeung Ho ◽  
Stefano Cacciatore ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Fatty Acid ◽  
Androgen Receptor ◽  
Cancer Progression ◽  
Fatty Acid Synthase ◽  
De Novo ◽  
Metabolic Reprogramming ◽  
De Novo Lipogenesis ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

A hallmark of prostate cancer progression is dysregulation of lipid metabolism via overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatty acid synthesis. Metastatic castration-resistant prostate cancer (mCRPC) develops resistance to inhibitors of androgen receptor (AR) signaling through a variety of mechanisms, including the emergence of the constitutively active AR variant V7 (AR-V7). Here, we developed an FASN inhibitor (IPI-9119) and demonstrated that selective FASN inhibition antagonizes CRPC growth through metabolic reprogramming and results in reduced protein expression and transcriptional activity of both full-length AR (AR-FL) and AR-V7. Activation of the reticulum endoplasmic stress response resulting in reduced protein synthesis was involved in IPI-9119–mediated inhibition of the AR pathway. In vivo, IPI-9119 reduced growth of AR-V7–driven CRPC xenografts and human mCRPC-derived organoids and enhanced the efficacy of enzalutamide in CRPC cells. In human mCRPC, both FASN and AR-FL were detected in 87% of metastases. AR-V7 was found in 39% of bone metastases and consistently coexpressed with FASN. In patients treated with enzalutamide and/or abiraterone FASN/AR-V7 double-positive metastases were found in 77% of cases. These findings provide a compelling rationale for the use of FASN inhibitors in mCRPCs, including those overexpressing AR-V7.

Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression

2011 ◽  
pp. 1-15
Author(s):  
T. C. Thompson ◽  
S. A. Tahir ◽  
L. Li ◽  
M. Watanabe ◽  
K. Naruishi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Cancer Progression ◽  
Caveolin 1
Sign in / Sign up

Export Citation Format

Share Document